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NEOPLASIA
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is
fused to the platelet-derived growth factor receptor b gene in atypical chronic
myeloid leukemia with t(5;10)(q33;q22)
Juerg Schwaller, Ema Anastasiadou, Danielle Cain, Jeff Kutok, Sarah Wojiski, Ifor R. Williams, Roberta LaStarza, Barbara Crescenzi,
David W. Sternberg, Patrick Andreasson, Roberta Schiavo, Salvatore Siena, Cristina Mecucci, and D. Gary Gilliland
The molecular cloning of the t(5;10)(q33;
q22) associated with atypical chronic my-
eloid leukemia (CML) is reported. Fluores-
cence in situ hybridization (FISH),
Southern blot, and reverse transcriptase–
polymerase chain reaction analysis dem-
onstrated that the translocation resulted
in an H4/platelet-derived growth factor
receptor bR (PDGFbR) fusion transcript
that incorporated 5* sequences from H4
fused in frame to 3* PDGFbR sequences
encoding the transmembrane, WW-like,
and tyrosine kinase domains. FISH com-
bined with immunophenotype analysis
showed that t(5;10)(q33;q22) was present
in CD131 and CD141 cells but was not
observed in CD31 or CD191 cells. H4 has
previously been implicated in pathogene-
sis of papillary thyroid carcinoma as a
fusion partner of RET. The H4/RET fusion
incorporates 101 amino acids of H4, pre-
dicted to encode a leucine zipper dimer-
ization domain, whereas the H4/PDGFbR
fusion incorporated an additional 267
amino acids of H4. Retroviral transduc-
tion of H4/PDGFbR, but not a kinase-
inactive mutant, conferred factor-indepen-
dent growth to Ba/F3 cells and caused a
T-cell lymphoblastic lymphoma in a mu-
rine bone marrow transplantation assay
of transformation. Mutational analysis
showed that the amino-terminal H4
leucine zipper domain (amino acids 55-
93), as well as H4 amino acids 101 to 386,
was required for efficient induction of
factor-independent growth of Ba/F3 cells.
Tryptophan-to-alanine substitutions in the
PDGFbR WW-like domain at positions
566/593, or tyrosine-to-phenylalanine sub-
stitutions at PDGFbR positions 579/581
impaired factor-independent growth of
Ba/F3 cells. H4/PDGFbR is an oncopro-
tein expressed in t(5;10)(q33;q22) atypi-
cal CML and requires dimerization motifs
in the H4 moiety, as well as residues
implicated in signal transduction by
PDGFbR, for efficient induction of factor-
independent growth of Ba/F3 cells. (Blood.
2001;97:3910-3918)
© 2001 by The American Society of Hematology
Introduction
Constitutive activation of tyrosine kinases plays an important role
in the pathogenesis of solid tumors and hematological malignan-
cies. Chromosomal translocations and somatic mutations can cause
deregulation of tyrosine kinase activity, and an emerging number of
chromosomal translocations involving tyrosine kinases have been
identified in leukemia.1 An important consequence of these translo-
cations is the expression of fusion proteins with constitutive
tyrosine kinase activity. The most studied example is the t(9;22)(q34;
q22), resulting in expression of the BCR/ABL fusion, which is
present in approximately 95% of patients with chronic myeloid
leukemia (CML).2 Distinct genomic breakpoints within the BCR
gene result in different BCR/ABL fusion variants (p230, p210, and
p190). BCR causes oligomerization and activation of the ABL
tyrosine kinase activity and a broad spectrum of downstream
effectors, leading to transformation of hematopoietic cells.2 Other
fusion genes involving tyrosine kinases associated with hematopoi-
etic disorders include TEL/ABL, TEL/JAK2, and TEL/TRKC
fusions involving the FGFR1 gene (ZNF198/FGFR1, CEP110/
FGFR1, and FOP/FGFR1) and fusions involving the platelet-
derived growth factor receptor b (PDGFbR) gene.3-6 PDGFbR, a
member of the PDGF receptor family that includes the PDGFaR,
colony-stimulating factor 1 receptor, steel-factor receptor (c-kit)
and Flt3/FLK receptor, is characterized structurally by 5 immuno-
globulinlike extracellular loops and a split intracellular tyrosine
kinase domain.7 The first translocation involving the PDGFbR
gene was cloned from a chronic myelomonocytic leukemia (CMML)
patient with t(5;12)(q33;p13), resulting in fusion of the 59 terminal
region of the TEL(ETV6) gene (a member of the ets family of
transcription factors) to the transmembrane and tyrosine kinase
domains of the PDGFbR.8 Two other PDGFbR fusion genes have
subsequently been cloned. The t(5;14)(q33;q32) and t(5;7)(q33;
q11.2) rearrangements give rise to the CEV14/PDGFbR and
Huntingtin-interacting protein 1 (HIP1)/PDGFbR fusion genes,
respectively.9-10 The TEL/PDGFbR and HIP1/PDGFbR fusion
genes have been associated with CMML, whereas the CEV14/
PDGFbR fusion was cloned from a patient with acute monocytic
From the Division of Hematology, Department of Medicine, and the Department
of Pathology, Brigham and Women’s Hospital, and the Howard Hughes Medical
Institute, Harvard Medical School, Boston, MA; the Department of Pathology,
Emory University, Atlanta, GA; Divisione di Oncologia-Ematologia, Ospedale
Niguarda Ca’ Granda, Milan, and Sezione di Ematologia, Universita` degli studi
di Perugia, Italy.
Submitted June 6, 2000; accepted February 22, 2001.
Supported in part by a grant from the Swiss National Science Foundation
(3100-056984.99) (J.S.); by the Associazione Italiana per la Richerca sul
Cancro (C.M.); and by grants from the National Institutes of Health
(P01CA66996-01 and P01OK50654) and the MarJo Foundation (D.G.G.).
J.S. and E.A. contributed equally to this work.
Reprints: Juerg Schwaller, Institute de pathologie clinique, Hoˆpitaux
unive´rsitaire de Gene`ve, CMU, 1 Rue Michel Servet, Gene´ve, CH-1211,
Switzerland; or Gary Gilliland, Division of Hematology/Oncology, Brigham and
Women’s Hospital, Harvard Medical School, 4 Blackfan Circle, Boston, MA,
02115.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 U.S.C. section 1734.
© 2001 by The American Society of Hematology
3910 BLOOD, 15 JUNE 2001 z VOLUME 97, NUMBER 12
For personal use only. on September 17, 2019. at UNIV STUDI MILANO Biblioteca Polo San Paolo www.bloodjournal.orgFrom 
leukemia in relapse. CMML is a subtype of myelodysplastic
syndrome characterized by dysplastic monocytosis, variable bone
marrow fibrosis, and progression of acute leukemia; its clinical
phenotype is similar to CML, but is lacking the Philadelphia
chromosome.11 TEL/PDGFbR and HIP1/PDGFbR transform he-
matopoietic cells in vitro and in vivo.12-15
Constitutive activation of tyrosine kinases due to chromosomal
rearrangements or somatic mutations is also observed in solid
tumors.16 Overexpression and somatic mutation of HER-2/p185neu
and cMET are observed in breast carcinomas and renal or thyroid
carcinoma.17,18 Alterations of the RET proto-oncogene, which
encodes for a receptor tyrosine kinase, are responsible for the
development of multiple endocrine neoplasia types 2A and 2B,
Hirschsprung disease, and papillary thyroid cancer.19 Gene rear-
rangements leading to fusion of its tyrosine kinase domain to the 59
terminal region of other genes generate the RET/PTC oncogenes,
which are associated with human papillary carcinoma.20 Seven
different types of RET rearrangement (PTC 1-7) have been
molecularly characterized.21 RET/PTC1 is the result of a paracen-
tric inversion of the long arm of chromosome 10 inv(10)(q11.2q21),
fusing the terminal amino acid 101 of the H4(D10S170) gene to the
intracellular split tyrosine kinase domain of RET. This rearrange-
ment is observed in approximately 20% of human papillary
carcinomas.22 The H4(D10S170) gene encodes for a 585–amino
acid protein with no significant homology to known genes and has
unknown function.23 In vitro studies showed that the leucine zipper
region of H4 included in the fusion is responsible for the
dimerization of the PTC1 oncoprotein and is essential for tyrosine
hyperphosphorylation and transformation in vitro.24
Here we present the molecular characterization of a patient with
atypical CML with t(5;10)(q33;q22). Initial classical karyotypic
analysis showed a reciprocal translocation t(5;10) in myeloid
progenitor cells of the patient.25 Using fluorescence in situ hybrid-
ization (FISH), Southern blot, and rapid amplification of comple-
mentary DNA (cDNA) ends (RACE)–polymerase chain reaction
(PCR) techniques, we show that the translocation is present only in
the patient’s myeloid cells and results in fusion of the H4(D10S170)
gene to the transmembrane and tyrosine kinase domains of the
PDGFbR. In vitro experiments show that expression of the
H4/PDGFbR fusion gene transforms interleukin-3 (IL-3)–depen-
dent Ba/F3 cells to factor independence. Moreover, in vivo
transforming activity of the H4/PDGFbR fusion is demonstrated in
a murine bone marrow reconstitution assay. These data show that
rearrangements of the H4(D10S170) gene can not only contribute
to carcinogenesis by activating RET in papillary carcinomas but
also lead to hematopoietic transformation in an H4/PDGFbR
fusion gene associated with atypical CML.
Materials and methods
FISH and “fiction” analysis
FISH was performed as previously described.26 The breakpoint on chromo-
some 5 was investigated by means of the cosmid probe cosmid B (cosB)
(kindly provided by Dr W. M. Roberts, M. D. Anderson Cancer Center,
Houston, TX),8 assigned to the PDGFbR gene at band 5q33. The
breakpoint on chromosome 10 was narrowed by applying 2 yeast artificial
chromosomes (YACs), 781F5 and 876H2, for bands 10q21.3 and 10q22.1,
respectively. In each experiment, the centromeric chromosome 10 probe
D10Z1 was added. Dual-color FISH was performed with cosB labeled with
digoxigenin, and PAC29F6 for the H4/D10S170 gene,27 labeled with biotin.
The “fiction” method was adapted from Weber-Matthiesen et al.28
Cytospins were prepared from mononuclear cells that were obtained from
the patient’s peripheral blood and stored at 220°C without fixation. After
thawing, the slides were fixed in acetone at room temperature for 10
minutes and air-dried. They were then incubated with a monoclonal
antibody for 30 minutes at room temperature, and staining was performed in
a 3-step technique with the following antibodies: Cy3-conjugated poly-
clonal goat antimouse, rabbit antigoat, and donkey antirabbit (Jackson
Laboratory, Bar Harbor, ME; Dianova, Hamburg, Germany); and the
following monoclonal antibodies: anti-CD3, anti-CD13, anti-CD14, anti-
CD20, and anti-CD19 (all from Dako, Glostrup, Denmark). After immuno-
staining, the slides were fixed in Carnoy fixative (methanol-to-acetic acid,
3:1) for 10 minutes, followed by 1% paraformaldehyde for 10 minutes,
washed in distilled water; dehydrated in an ethanol series; and hybridized
with cosB for the PDGFbR. The biotinylated DNA was detected by
incubation with fluorescein isothiocyanate (FITC)–conjugated avidin, fol-
lowed by biotinylated goat antiavidin antibody, followed by a second
incubation with FITC-conjugated avidin. The immunophenotype and
hybridization signals were evaluated simultaneously on an Olympus
microscope with filter sets for Cy-3 and FITC (Olympus Optical, Japan).
DNA isolation and Southern blot analysis
DNA was isolated from buffy-coat preparations of peripheral blood from
the patient and a normal individual after informed consent had been
obtained. The patient’s clinical history has been described previously.25
DNA was prepared by means of a Purgene DNA isolation kit (Gentra
Systems, Minneapolis, MN) according to the manufacturer’s protocol. After
enzymatic digestion with restriction endonucleases and electrophoretic
separation, the genomic DNA was blotted to Hybond-N1 nylon membranes
(Amersham, Arlington Heights, IL) by alkaline transfer. The PDGFbR
genomic probe was a 1.1-kilobase (kb) HindIII-XhoI fragment prepared
from PDGFbR cosB.8 Probes were labeled with 32P by random priming,
and Southern hybridizations were performed as described.29
Breakpoint cloning
We isolated 1.6 mg poly(adenylic acid), or poly(A), RNA from 60 3 106
cells from the patient’s buffy-coat cells using the Quickprep Micro
messenger RNA purification kit (Pharmacia Biotech, Uppsala, Sweden).
Anchored PCR was performed to clone the chromosome 10 partner gene by
means of a 59-3 RACE kit (Boehringer Mannheim, Mannheim, Germany).
In brief, 500 ng poly(A) RNA was reverse-transcribed by means of avian
myeloblastosis virus (AMV) reverse transcriptase and PDGFbR oligonucle-
otide primer 1873R at 55°C. PDGFbR primers have been previously
described in detail.8,10 A poly-A tail was appended to the purified cDNA by
means of terminal transferase and deoxyadenosine triphosphate. The tailed
cDNA was amplified (94°C for 2 minutes, 94°C for 15 seconds, annealing
at 58°C for 30 seconds, elongation for 40 seconds, and cycle elongation of
20 seconds after 10 cycles of a total of 35 cycles) by means of oligo
deoxythymidine anchor primer (59-GAC CAC GCG TAT GCA TGT CGA
CTT TTT TTT TTT TTT TT-39) and an internal PDGFbR primer 1848R.
We re-amplified 1 mL of the diluted first-round PCR product (1:20) in a
nested PCR reaction using the same conditions as the first round with a PCR
anchor primer (59-GAC CAC GCG TAT CGA TGT CGA C-39) and the
PDGFbR internal primer 1829R. Specific bands were detected after 2
rounds of PCR by direct visualization on an agarose gel. Two fragments,
250 base pairs (bp) and 400 bp, appeared in 2 separate experiments and
were subcloned into pCR2.1-TOPO (Invitrogen, Carlsbad, CA) and se-
quenced. The DNA sequence was then compared with sequences in the
GenBank by means of the advanced BlastN screening.
Reconstruction of a full-length fusion cDNA for
expression experiments
A full-length cDNA clone of the fusion was generated as follows. The
H4/PDGFbR breakpoint was amplified by means of a forward PDGFbR
primer with H4-specific anchor that incorporates a unique StuI site 59 of the
breakpoint, together with a PDGFbR reverse primer covering a unique
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SacII site 250 bp 39 of the breakpoint by means of Pfu-polymerase
(Stratagene, San Diego, CA) according to the manufacturer’s recommenda-
tions. The product was subcloned into pcDNA3 (Invitrogen) containing an
H4(D10S170) full-length cDNA clone in reverse orientation, cloned from
pGEM3Z-H4 cDNA,23 and sequenced to confirm that no mutations had
been introduced in the PCR step. The 39 end of the PDGFbR cDNA was
added by isolating the fragment from pBluescript.TEL/PDGFbR cDNA8
and cloning it into the unique SacII site. This full-length reverse H4/
PDGFbR clone was then subloned in pBluescript, pMSCVneo, and
pMSCV-GFP (the pMSCV retroviral expression vectors were kind gifts
from R. Hawley, University of Toronto, ON, Canada, and W. Pear,
University of Pennsylvania, Philadelphia). Expression of the H4/PDGFbR
fusion protein from the full-length H4/PDGFbR cDNA clone was con-
firmed by means of an in vitro transcription-translation reaction kit
(Promega, Madison, WI) (not shown).
Expression of H4/PDGFbR in primary patient cells
Expression of the H4/PDGFbR fusion was studied in peripheral blood cells
(buffy-coat preparation) from the patient and in cells of a normal healthy
donor. Total RNA was isolated by means of an RNA isolation kit
(RNA-STAT-60) (Tel-Test, Friendswood, TX) followed by reverse transcrip-
tion of 1 mg total RNA by means of AMV-RT (1st Strand cDNA Synthesis
Kit) (Boehringer Mannheim) following the manufacturer’s instructions. A
nested-PCR approach was used as follows: H4.300F (59CAA GCC AGG
GCT GAG CAG GAA GAA TTC 39) and H4.720F (59GCT CCA CCA
TCG CCT AGA GAT ATC TCC ATG 39), each with PDGFbR (1848R) for
the first cycle; 1 mL of a 1:10 dilution of the first round was used for the
second round with the same H4 primers in combination with the PDGFbR
(1829R) primer. The PCR cycle parameters were 10 cycles at 94°C for 30
seconds, 65°C (decreasing 1°C per cycle) for 30 seconds, and 72°C for 30
seconds, followed by 30 cycles of 94°C, 55°C, and 72°C for 30 seconds
each and a final extension of 7 minutes at 72°C. To detect the reverse
PDGFbR/H4 product, the PDGFbR.F1 (59GGA GAC TAA CGT GAC
GTA CTG 39) primer was used for the first round in combination with
H4.R1 (59CAG GAC TGT TGC TTC TCC GTG 39) and H4.R2 (59GCT
CCA TTG GAT GAG TCC CAA C 39) primers; for the second round, the
PDGFbR.F2 (59GAG TTT GAG GTG GTG AGC AC 39) primer was used
with the same H4 primers. For amplification of the H4 gene, primers
H4.300F and H4.720F with H4.R2 were used for the first round, followed
by a second round with the H4.R1 reverse primer. To assess the quality of
the transcribed cDNA, primers for b-actin were used: b-actin.2282F
(59GGG AAA TCG TGC GTG ACA TT 39) and b-actin.2583R (59GGA
GTT GAA GGT AGT TTC GTG 39).
Generation of H4/PDGFbR mutants and transformation studies
Mutants were generated by PCR by means of Pfu-polymerase (Stratagene)
according to the manufacturer’s recommendations and subcloned into the
retroviral expression vector MSCV-PGK-neo and MSCV-IRES-GFP. As
shown in Figure 5A, mutations that were generated included MSCV-H4/
PDGFbR-WW (W3 A [single-letter amino acid codes] substitutions at
positions 566/593 of the PDGFbR moiety); an H4/PDGFbR-F2 mutant
analogous to theTEL /PDGFbR-F2 previously described15; a kinase-
inactive MSCV-H4/PDGFbR2634R mutant,12 MSCV-H4/PDGFbRDLZ
lacking the H4(D10S170) leucine zipper domain (H4 amino acids 55-93);
and MSCV-H4/PDGFbR-DEX lacking amino acids 101-368 of H4(D10S170)
between the H4/RET and H4/PDGFbR breakpoints. All PCR-generated
fragments were sequenced after subcloning to confirm the correct sequence,
and the cDNA clones were translated in vitro to confirm expression of a
protein of the expected molecular weight. To test for transforming ability,
H4/PDGFbR clones were expressed in the IL-3–dependent hematopoietic
cell line Ba/F3, by retroviral transduction with the use of retroviral
supernatants generated by transient double transfection of pMSCV and pIk6
into 293T cells as described previously.29 At 48 hours after infection, cells
were washed and screened for survival in medium lacking IL-3. The same
experiment was also performed by means of stably transfected cells with
MSCV-H4/PDGFbR-PGK-neo and the mutants, preselected in G418 (1
mg/mL), for 7 to 10 days.29
To characterize the in vivo transforming activity of the H4/PDGFbR
fusion, a murine bone marrow transplantation (BMT) assay was performed
as described previously.15,29 Briefly, donor mice were treated with 5-FU
(150 mg/kg) 5 days prior to harvest of bone marrow. Bone marrow cells
were incubated for 48 hours ex vivo in media that included IL-3, IL-6, and
stem cell factor as described15,29 and transduced by spinfection with viral
supernatants of the murine ecotropic retrovirus MSCV containing the
constructs noted in the text. One million transduced whole bone marrow
cells were then injected by tail vein into lethally irradiated syngeneic
recipeint mice (Balb/C, 450 cGY 3 2) as previously described.15,29 A total
of 16 recipient mice were transplanted with bone marrow transduced with
MSCV retrovirus containing the full-length H4/PDGFbR fusion gene.
Preparation of tissues for histologic examination and flow cytometric
analysis was performed as described previously.29
Results
The PDGFbR gene is rearranged in myeloid lineage cells
harboring the t(5;10)(q33;q22)
To localize the breakpoint, FISH of metaphase chromosome
preparations of bone marrow cells from the patient with atypical
CML and t(5;10) as a single karyotypic abnormality was per-
formed. As described previously, the abnormal karyotype, as
assessed by conventional cytogenetics, was present in myeloid
precursor cells.25
FISH analysis with a chromsome 5q33–specific probe, cosB,
which includes a portion of the genomic sequence of the PDGFbR
gene, gave a hybridization signal on the normal 5, and a split
hybridization signal on the der(5) and the der(10) generated by the
t(5;10) (Figure 1A). YACs 781F5 and 876H2, which are specific
for 10q21.3 to q22.1, hybridized with the normal chromosome 10
and with der(5). No signals were present on der(10) (Figure 1B). To
assess whether t(5;10) was present only in the patient’s myeloid
cells, a combination of immunostaining and FISH was performed.
As shown in Figure 2A-B, hybridization with cosB resulted in 3
hybridization signals in myeloid progenitor cells (CD 131, CD141),
whereas only 2 signals were observed in T (CD31) or B lineage
(CD191, CD201) cells (Figure 2C-D). Within the sensitivity of this
assay, these data indicate the presence of the t(5;10) balanced
reciprocal in myeloid lineage cells, but not in lymphoid cells of this
patient with atypical CML.
The clinical, cytogenetic, and FISH data from this patient were
similar to those observed in previously reported cases of CMML
with the t(5;12)(q33;p12) TEL/PDGFbR and the t(5;7)(q33;q11.2)
HIP1/PDGFbR fusion genes, respectively.8,10 In those previous
examples, the PDGFbR cases, the chromosomal breakpoint was
identified by means of a 1.1-kb XhoI/HindIII genomic PDGFbR
probe derived from cosB.8,10 Southern blot analysis using this
genomic PDGFbR fragment as a probe demonstrated rearrange-
ment of the PDGFbR gene in 3 out of 5 restriction-enzyme digests
of the patient’s DNA, but not in the normal cDNA (Figure 3). These
data demonstrated that the chromosome 5 breakpoint was at or near
the same intron of the PDGFbR gene as in the t(5;12)(q33;p13) and
t(5;7)(q33;q11.2) translocations.8,10
Identification of the H4(D10S170) gene as fusion partner to the
PDGFbR gene in t(5;10)(q33;q22)
The chromosome 10 partner was identified by means of anchored
PCR with PDGFbR primers to amplify the fusion transcript from
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the patient’s peripheral blood cell cDNA. Analysis of the amplified
cDNA clones showed 2 clones of 250 and 400 bp of non-PDGFbR
sequence encoding an open reading frame fused to the transmem-
brane and tyrosine kinase–encoding regions of the PDGFbR gene
(Figure 4A). A database search demonstrated that this sequence
was identical to the coding sequence of the H4(D10S170) gene
located on chromosome 10q21.23
The H4(D10S170) cDNA is ubiquitously expressed and en-
codes a protein of unknown function and no significant homology
to any mammalian gene. The protein has a predicted alpha helical
conformation similar to the myosin heavy-chain tail, 2 putative
leucine zipper domains, and a putative SH3 domain at the
C-terminus, and it has been suggested to be a cytoskeletal protein.23
H4(D10S170) is involved in RET rearrangements as a result of a
paracentric inversion of chromosome 10q inv(10)(q11.2q21) asso-
ciated with about 25% of human papillary thyroid carcino-
mas.20,23,30 In these carcinomas, the genomic breakpoint in
H4(D10S170) occurs in intron 1.31,32 The resulting oncogene
RET/PTC1 (papillary thyroid carcinoma gene 1) is formed by
in-frame fusion of 59 sequences from the H4(D10S170) gene
(amino acids 1-101) to the RET gene, 39 bp 39 of RET tyrosine
kinase–coding sequences.20 In contrast to RET/PTC1 (Figure 4A),
the breakpoint within the H4 gene in t(5;10)(q33;q21) lies 39 of the
breakpoint in the H4/RET fusion and fuses the first 368 amino acids
of H4(D10S170) to the transmembrane and tyrosine kinase do-
mains of the PDGFbR. To confirm expression of the H4/PDGFbR
fusion transcript in primary leukemic cells from the patient, reverse
transcriptase (RT) PCR analysis was performed with 2 different
pairs of H4/PDGFbR primers. H4/PDGFbR fusion transcripts
were detected in the patient’s peripheral blood cells but not in the
normal control (Figure 4B). Expression of the reciprocal
PDGFbR/H4 fusion was not detected (data not shown), which is
similar to results obtained in patient samples harboring the
TEL/PDGFbR and HIP1/PDGFbR gene rearrangements.8,10 The
normal H4(D10S170) allele is deleted in a papillary thyroid cancer
cell line (TPC-1) carrying a RET/PTC1 fusion gene.27 However,
FISH analysis of t(5;10)(q33;q21) cells showed no evidence of loss
of the residual allele, and the H4(D10S170) transcript was detect-
able in leukemic cells containing the translocation, indicating the
presence of a functional residual H4(D10S170) allele (Figure 4C).
Collectively, these data demonstrate that t(5;10)(q33;q21) results in
fusion of H4(D10S170) to the PDGFbR and that the H4/PDGFbR
fusion transcript, but not the reciprocal, is expressed in the patient’s
myeloid lineage cells.
The H4/PDGFbR fusion gene has transforming activity in vitro
and in vivo
To characterize the biological properties of the H4/PDGFbR
fusion, a full-length cDNA clone was constructed and subcloned
into MSCV-PGK-neo and MSCV-IRES-GFP retroviral expression
vectors (Figure 5A). Murine IL-3–dependent hematopoietic Ba/F3
cells were retrovirally transduced with MSCV-H4/PDGFbR and
assayed for growth-factor independence. Ba/F3 cells expressing
H4/PDGFbR were generated either by retroviral transduction with
MSCV-H4/PDGFbR-neo and selection with G418 or by transduc-
tion with MSCV-H4/PDGFbR-GFP without selection (data not
shown). These cells were able to sustain log-phase growth in the
absence of IL-3, whereas Ba/F3 cells transduced with empty vector
died rapidly after IL-3 depletion (Figure 5B). In vitro transforming
activity of the H4/RET and the TEL/PDGFbR is dependent on the
presence of the leucine zipper and pointed dimerization domains in
H4 and TEL, respectively.12,24 To determine which structural
components of the H4/PDGFbR fusion were required for transfor-
mation of Ba/F3 cells to factor-independent growth, several
mutants were constructed (Figure 5A). MSCV-H4/PDGFbRDLZ
lacks the 59-leucine zipper domain (amino acids 55-93) and
MSCV-H4/PDGFbR-DEX lacks the portion of H4(D10S170) gene
that is present in the H4/PDGFbR fusion but absent in the
corresponding H4/RET fusion (H4 amino acids 101-368). Thus,
transformation of Ba/F3 cells to factor-independent growth by
H4/PDGFbR, in a 4-day assay after IL-3 deprivation, required the
presence of the amino-terminal leucine zipper domain. In addition,
Figure 1. FISH analysis of the t(5;10)(q33;q22) in primary patient cells. (A) FISH
analysis using PDGFbR- and H4-locus–specific probes. CosB, a PDGFbR-specific
genomic probe, gave 3 hybridization signals on normal 5 and on der(5) and der(10)
originating from t(5;10), respectively. Both YACs 781F5 and 876H2, for 10q21.3 to
q22.1, hybridized with the normal chromosome 10 and with the der(5). No signals
were present on der(10). (B) Dual-color FISH with CosB (red) and PAC29F6 (green)
showed the presence of a fusion signal on der(5), whereas a green signal (PAC29F6)
was present on the normal 10, and a red signal was seen (CosB) on the normal 5 and
the der(10).
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H4 coding sequences that are present in H4/PDGFbR but absent in
H4/RET were required for full transforming activity (Figure 5B).
A recent report has proposed an important role for the WW-like
domain (amino acids 566/593), which is C-terminal to the PDGFbR
transmembrane region, for normal signal transduction mediated by
the native PDGFbR.33 We found that a WW mutation (Figure 5A)
also impaired the ability of the H4/PDGFbR fusion to confer
factor-independent growth to Ba/F3 cells (Figure 5B). In addition,
an H4/PDGFbR F2 mutant (Y3 F mutants of the tyrosines 579
and 581, near the PDGFbR transmembrane domain) was gener-
ated34 (Figure 5A). These tyrosines are important for PDGFbR
signal transduction mediated by interaction with the SH2-
containing SRC protein and STAT5 family members,35 and an
analogous TEL/PDGFbR-F2 mutant cannot induce myeloprolifera-
tive disease in murine BMT models.15 The H4/PDGFbR-F2
mutant also had impaired ability to induce factor-independent
growth in Ba/F3 cells (Figure 5B). Western blot analysis of whole
cell lysates using an anti-PDGFbR antibody demonstrated expres-
sion of H4/PDGFbR and related mutants at the expected molecular
weights. (Figure 5C). No differences in tyrosine kinase activity
could be detected as a consequence of these mutations as assessed
by phosphotyrosine blots to detect autophosphorylation.
We tested the transforming activity of the H4/PDGFbR fusion
in vivo using a murine BMT assay. In previous studies, we
demonstrated that transplantation of primary bone marrow cells
that have been transduced with a retrovirus encoding a tyrosine-
kinase fusion gene results in induction of a lethal hematological
disease in syngeneic recipient animals.15,29,36,37 Murine bone mar-
row was transduced with retroviral supernatants containing MSCV-
H4/PDGFbR-GFP (16 animals), MSCV-H4/PDGFbR-634R-GFP
(8 animals), and MSCV-TEL/PDGFbR-GFP (8 animals), and one
million cells were transplanted by tail-vein injection into lethally
irradiated syngeneic hosts. Control animals that received bone
marrow transduced with the TEL/PDGFbR retrovirus developed a
rapidly lethal myeloproliferative disease with a latency of 25 to 30
days, as previously reported,15 whereas the kinase-inactive MSCV-
H4/PDGFbR-634R-GFP caused no disease with 8 months of
follow-up. In contrast, H4/PDGFbR induced an aggressive T-cell
lymphoblastic lymphoma/leukemia with prolonged latency (me-
dian, 150 days post-transplant), as assessed by morphologic
(Figure 6A-C) and flow-cytometric analysis (Figure 6D). Retrovi-
ral integration was confirmed by Southern blot analysis (Figure
Figure 3. Southern blot analysis of DNA from leukemia cells with t(5;10)(q33;
q22). Genomic DNA was isolated mononuclear cells from Ficoll-Hypaque density
gradient sedimentation of peripheral blood from the patient and a normal donor and
was digested (10 mg) with 5 different restriction endonucleases. The Southern blot
was probed with a 1.1-kb (XhoI/HindIII) genomic PDGFbR probe. Rearrangements
were evident in patient DNA when the restriction endonucleases HindIII, PstI, or PvuI
were used (lanes 3-8).
Figure 2. Simultaneous phenotypic and genotypic analysis
on a cytospin prepared from peripheral blood cells. Monoclo-
nal antibody (red), PDGFbR probe (green). (A, B) CosB gave 3
hybridization signals on CD131 or CD141 cells, respectively,
indicating the presence of the t(5;10)(q33;q22) with a split PDGFbR
signal in these myeloid lineage cells. (C, D) Only 2 signals were
present in the CD31 or CD191 cells, respectively, indicating that
these lymphoid cells lack the translocation.
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Figure 4. Structure and RT-PCR of H4/PDGFbR fusion. (A)
Structure of the H4/PDGFbR fusion. H4 is fused at amino acid
381 in frame to the PDGFbR gene beginning at amino acid
528. The breakpoint within PDGFbR is identical to that in the
TEL /PDGFbR and HIP1/PDGFbR fusions. (B) RT-PCR of the
H4/PDGFbR fusion. RNA was extracted from leukemic cells
containing the t(5;10)(q33;q22) and from a normal donor and
was used as a template for RT-PCR as described in “Materials
and methods.” Two sets of H4/PDGFbR primers, denoted
300F and 720F, were used. H4/PDGFbR-specific transcripts
were detected in the leukemic sample but not in the normal
control. (C) RT-PCR of H4(D10S170) was also performed to
demonstrate H4(D10S170) expression in both normal and
patient samples. As expected, signal was seen in patient,
donor, and H4 containing plasmid with the use of the 720F
primer set, but not in the H4/PDGFbR plasmid.
Figure 5. Structure and transforming properties of H4/PDGFbR and related mutants. (A) Schematic diagram of H4/PDGFbR fusion and related mutants. H4/PDGFbR
(wt) is the wild-type full-length cDNA. H4/PDGFbR-DEX lacks amino acids 101 to 368 of H4; H4/PDGFbR-DLZ lacks the leucine zipper domain from amino acids 55 to 93 of H4
moiety; H4/PDGFbR-WW contains 2 W3 A substitutions at positions 566/593 of the PDGFbR gene; H4/PDGFbR-634R is a kinase-inactive mutant; and H4/PDGFbR-F2
contains 2 Y3 F mutations of residues 579/581 of the PDGFbR portion of the fusion. (B) H4/PDGFbR transformation of Ba/F3 cells. H4/PDGFbR was retrovirally transduced
by retrovirus into Ba/F3 cells, followed by selection with G418 (1 mg/mL) in the presence of IL-3. After 7 days, the cells were washed and IL-3 was withdrawn. Cells were
counted every 24 hours with the use of trypan blue solution (0.4%) to distinguish between viable and nonviable cells. None of the H4/PDGFbR mutants tested were able to
efficiently induce IL-3–independent growth, although longer term culture allowed for eventual outgrowth of IL-3–independent clones (data not shown). Control experiments
demonstrated that TEL /JAK2, but not a PGK-neo empty vector, conferred factor independence to Ba/F3 cells. (C) Expression of H4/PDGFbR and related mutants. Expression
of H4/PDGFbR and related mutants was confirmed by Western blot analysis of Ba/F3 whole cell lysates by means of anti-PDGFbR antibody as described in “Materials and
methods.” Expected band sizes are H4/PDGFbR, 110 kd; H4/PDGFbR DEX, 85 kd; and H4/PDGFbR DLZ, 105 kd.
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7A), and the neoplastic cells were monoclonal in spleen and bone
marrow (Figure 7B). An additional, less-intense band indicative of
biclonal disease was identified in lymph node and thymus. These
data demonstrate that the H4/PDGFbR fusion resulting from
t(5;10)(q33;q22) has transforming potential in vitro and in vivo.
Discussion
We have cloned a novel fusion between the H4(D10S170) gene on
chromosome 10q and PDGFbR on 5q, the result of a reciprocal
t(5;10)(q33;q22) in a patient with atypical CML. H4(D10S170) encodes
a ubiquitously expressed protein of unknown function and has been
previously characterized as fusion partner of the RET receptor tyrosine
kinase,20,22,23 whose ligand is the glial cell line–derived neurotrophic
factor.38,39 The H4/RET fusion is one of 6 known RET rearrangements
associated with human papillary thyroid carcinoma and is found in
approximately 25% of the cases.21
Both fusion genes involving the H4(D10S170) gene, H4/PDGFbR
and H4/RET, are associated with a specific disease phenotype. Rearrange-
ments of RET occur exclusively in papillary thyroid carcinomas,
whereas PDGFbR fusions have been associated with acute myeloid
leukemia and chronic myeloproliferative syndromes. Both H4 fusion
genes (H4/RET and H4/PDGFbR) have transforming activity in vitro
and in vivo. In vitro transforming activity of H4/RET depends on the
presence of the leucine zipper domain at the 59 end of H4(D10S170),
which acts as a dimerization/oligomerization motif leading to activation
of the fused kinase domain.24 In addition, targeted expression of the
RET/PTC1 oncogene induces papillary thyroid carcinomas in mice.40,41
There are several differences between H4/PDGFbR and
H4/RET. The H4/RET genomic breakpoint occurs in H4 intron 1
and thus incorporates only the first exon of the H4(D10S170)
gene. In contrast, the H4/PDGFbR contains an additional 801
bp of H4(D10S170) coding sequence. The function of this
domain is unknown, although a protein sequence analysis
reveals a series of 5 3 29 tandem repeats (positions 106-235,
SWISS-PROT Q16204) and a small second putative leucine
zipper domain in this region (positions 265-278, Pfam 4.2,
HMM search). H4/PDGFbR conferred factor-independent growth
to the IL-3–dependent hematopoietic cell line Ba/F3 cells.
Transformation activity was significantly impaired in H4/
PDGFbR-DLZ mutant lacking the amino-terminal leucine zip-
per domain, as well as the H4/PDGFbR-DEX mutant in which
H4 coding sequences unique to the H4/PDGFbR fusion were
deleted. These data suggest that there are functional components
in each of these domains that are required for full transforming
Figure 7. Analysis of proviral integration in disease tissue in transplanted mice.
Southern blot analysis was performed with 10 mg DNA extracted from murine tissues.
(A) DNA was digested with the restriction enzyme NheI, which cleaves in the viral
long-terminal repeat sequences and demonstrates viral integration. The expected
DNA band size is 5.8 kb. (B) Clonality of the disease was assessed by digestion with
EcoRI, which cleaves once within the provirus. There is clonal disease in spleen and
bone marrow, and the presence of a second clone was detected in lymph node and
thymus. (C) Restriction sites within the proviral sequence.
Figure 6. Histopathologic and flow-cytometric analysis of
mice transplanted with bone marrow transduced by H4/
PDGFbR retrovirus. Mice transplanted with bone marrow trans-
duced with H4/PDGFbR retrovirus develop a lethal hematopoietic
malignancy after a latency of approximately 150 days. The
disease is characterized by proliferation of immature T cells
(CD41/1 and CD81/1 cells), with infiltration of spleen (A, high-
power view), bone marrow (B, low-power view), and lymph node
(C, high-power view). Flow cytometry of the lymph node (D)
demonstrates a predominant CD41/1CD81/1 T-cell population.
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activity in the Ba/F3 assay. Additional mutational analysis will
be required to further delineate these critical regions.
Mutations of the juxtamembrane tyrosine residues or in the WW-like
domain of the H4/PDGFbR also impaired factor-independent growth of
Ba/F3 cells. First, the H4/PDGFbR-F2 mutant contains Y3 F substitu-
tions at PDGFbR residues 579/581 and participates in signal transduc-
tion to SRC and STAT family members. In the context of the
H4/PDGFbR fusion, phenylalanine substitutions at positions 579/581
abrogate induction of IL-3–independent growth of Ba/F3 cells. In
addition, an analogous TEL/PDGFbR F2 mutant also has impaired
ability to confer factor-independent growth to Ba/F3 cells (D.W.S. and
D.G.G., unpublished observation, 2000) and is incapable of causing a
myeloproliferative disease in a murine BMT model.15 Taken together,
these data suggest that these juxtamembrane residues play an important
role in the myeloproliferative phenotype associated with the H4/
PDGFbR and TEL/PDGFbR fusion proteins. Second, the W3A
point mutations in the WW-like domain of H4/PDGFbR impaired
IL-3–independent survival of Ba/F3 cells. These 2 tryptophan residues
are characteristic of WW-domains,42 and a single amino acid substitu-
tion in the WW-like domain of the native PDGFbR causes constitutive
activation of the receptor.43 WW domains have been shown to associate
with proline-rich motifs44-46 and with protein-phosphoserine and
phosphothreonine motifs.47 We speculate that the WW-like domain
of the H4/PDGFbR fusion mediates direct interaction with down-
stream effector molecules and that disruption of these interactions
through mutation impairs transformation of hematopoietic cells.
Further analysis of the signal transduction and transforming
properties of these mutants in vivo will be necessary to identify the
relevant downstream effector molecules.
We next tested in vivo transforming activity of H4/PDGFbR in
a murine BMT model.15,29 In this assay, expression of the tyrosine
kinase fusion genes BCR/ABL, TEL/JAK2, and TEL/PDGFbR
induces a lethal myeloproliferative syndrome with an average
latency of 25 to 30 days.15,29,36,37 However, mice transplanted with
bone marrow transduced with a retrovirus encoding H4/PDGFbR
developed a long-latency T-cell lymphoblastic lymphoma/leuke-
mia. These data demonstrate that H4/PDGFbR transforms primary
hematopoietic cells in the murine BMT assay. In addition, these
data show that, although there is myeloid-lineage restriction of the
t(5;10)(q33;q22) translocation in human atypical CML, the H4/
PDGFbR fusion is capable of transformation of lymphoid cells. In
a control experiment, mice transplanted with TEL/PDGFbR died
of a myeloproliferative disease within 30 days, as expected. There
are several possible explanations for the disparity in latency and
phenotype between the TEL/PDGFbR and H4/PDGFbR fusions,
including variable contribution to transformation by the H4 and
TEL moieties, respectively. However, the most likely explanation
is that H4/PDGFbR viral supernatants had a substantially lower
titer than the TEL/PDGFbR supernatants (1025 vs 1026/mL,
respectively), despite repeated efforts to generate higher titer
H4/PDGFbR retrovirus. TEL/PDGFbR BMT performed with viral
supernatant titers of 1025/mL also gives long-latency, clonally
derived lymphoblastic lymphoma (D.W.S. and D.G.G., unpub-
lished observation, 2000).
Another case of myeloproliferative disease associated with
t(5;10)(q33;q22) and an H4/PDGFbR fusion has recently been
reported by Cross and colleagues, indicating that this is a recurring
gene rearrangement.48
In summary, the H4/PDGFbR fusion has transforming activity
both in vitro and in vivo. Mutational analysis shows that transfor-
mation is dependent on the PDGFbR-kinase domain. In addition,
induction of factor-independent growth is impaired by deletion of
H4 sequences encoding the amino-terminal leucine zipper domain.
Induction of factor-independent growth is also impaired by dele-
tion of H4 sequences that are present in the H4/PDGFbR fusion,
but absent in the H4/RET fusion associated with papillary thyroid
carcinoma. In addition, mutation of PDGFbR juxtamembrane
tyrosine residues 579/581 to phenylalanine, as well as W3 A
mutations of the WW-like domain, significantly impairs transforma-
tion in this assay. Further analysis of related mutations and assays
in the murine BMT assay should provide additional insights into
the mechanisms of transformation by the increasing number of
PDGFbR gene rearrangements associated with human leukemias.
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